• NOVEL THERAUPETICS IN THE TREATMENT OF TYPE-II DIABETES

Abstract

Type II diabetes is characterised by insulin resistance accompanied by progressive deficiency in insulin secretion. Type II diabetes is increasingly a common disease that is closely associated with obesity. Observational studies and clinical trials show that improved glycimic control reduces micro (eye, kidney and nerve) and macro (heart) vascular complications. However the effect of specific oral diabetes medications on these outcomes is less certain.

As new classes of medications have become available for the treatment of diabetes, clinicians and patients have faced a bewildering array of oral medications with different mechanism of action. This review will be helpful as new classes of oral diabetic medication. Furthermore, it may help policy makers and insurers to have better insight when deciding on policies, relating to medication coverage.